AstraZeneca PLC
LSE:AZN
Intrinsic Value
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. [ Read More ]
The intrinsic value of one
AZN
stock under the Base Case scenario is
18 297.57
GBX.
Compared to the current market price of 11 498 GBX,
AstraZeneca PLC
is
Undervalued by 37%.
Fundamental Analysis
Balance Sheet Decomposition
AstraZeneca PLC
| Current Assets | 22.3B |
| Cash & Short-Term Investments | 6.5B |
| Receivables | 10.8B |
| Other Current Assets | 5B |
| Non-Current Assets | 74.4B |
| Long-Term Investments | 1.2B |
| PP&E | 9.6B |
| Intangibles | 59.3B |
| Other Non-Current Assets | 4.3B |
| Current Liabilities | 24.9B |
| Accounts Payable | 19.2B |
| Short-Term Debt | 568M |
| Other Current Liabilities | 5.1B |
| Non-Current Liabilities | 36B |
| Long-Term Debt | 27.6B |
| Other Non-Current Liabilities | 8.4B |
AZN Profitability Score
Profitability Due Diligence
AstraZeneca PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
Score
AstraZeneca PLC's profitability score is 58/100. The higher the profitability score, the more profitable the company is.
AZN Solvency Score
Solvency Due Diligence
AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
AstraZeneca PLC's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
AZN Price Targets Summary
AstraZeneca PLC
According to Wall Street analysts, the average 1-year price target for
AZN
is 12 783.33 GBX
with a low forecast of 6 185.98 GBX and a high forecast of 18 375 GBX.
Shareholder Return
AZN Return Decomposition
Main factors of price return
Market capitalization of
AZN
shares
increased
by
195.72%
over the past 5 years.
The primary factor behind the change was
an increase
in revenue growth from
22.3B
to
43.8B, leading to a
growth
in the market capitalization of AstraZeneca PLC by 121.67%.
Market capitalization of
AZN
shares
increased
by
195.72%
over the past 5 years.
The primary factor behind the change was
an increase
in revenue growth from
22.3B
to
43.8B, leading to a
growth
in the market capitalization of AstraZeneca PLC by 121.67%.
AZN Price
AstraZeneca PLC
| Average Annual Return | 15.11% |
| Standard Deviation of Annual Returns | 14.65% |
| Max Drawdown | -6% |
| Market Capitalization | 178B GBX |
| Shares Outstanding | 1 549 830 016 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
AstraZeneca PLC
Country
Industry
Market Cap
Dividend Yield
Description
AstraZeneca Plc is a holding company, which engages in the research, development, and manufacture of pharmaceutical products. The company is headquartered in Cambridge, Cambridgeshire and currently employs 83,100 full-time employees. The company went IPO on 2007-09-21. The firm focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The firm is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The firm has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.
Contact
IPO
Employees
Officers
The intrinsic value of one
AZN
stock under the Base Case scenario is
18 297.57
GBX.
Compared to the current market price of 11 498 GBX,
AstraZeneca PLC
is
Undervalued by 37%.
Sensibly Priced Quality
Significantly Undervalued
Magic Formula
High Growth
